New Delhi, Oct. 21 -- The pharmaceutical sector is witnessing a strong investor focus, supported by rising global demand, resilient exports, and strong domestic healthcare spending.

India's pharma exports crossed $30 billion (bn) in FY25, aided by United States Food and Drug Administration (US FDA) approvals and expanding generics reach.

However, pricing pressures in the US, regulatory scrutiny, and raw-material cost volatility continue to pose global headwinds.

We break down the two pharma players, comparing their business mix, profitability, and growth strategies to determine which one is stronger in India's evolving healthcare landscape.

Zydus Lifesciences Ltd is an integrated, global life sciences company operating across the enti...